

**ERECTILE DYSFUNCTION AND ITS ASSOCIATIONS
AMONG MEN WITH DIABETES**




BY

LASANTHA SANJEEWA MALAVIGE

Thesis submitted to University of Sri Jayewardenapura for the
award of the Degree of Doctor of Philosophy in Medicine on
**ERECTILE DYSFUNCTION AND ITS ASSOCIATIONS AMONG
MEN WITH DIABETES.**

I certify that the work presented in this thesis was carried out by me under the supervision of Professor S D Jayaratne, Professor S Sivayogan, Professor S Kathriarachchi and Dr J C Levy and a report of this work has not been submitted in whole or part to any other University or any other institution for another Degree or Diploma.



28/12/2009

Lasantha Malavige

Date


We certify that above statement made by the candidate is true and thesis is suitable for submission to the University of Sri Jayawardenepura for the purpose of evaluation.



28/12/09

Professor S D Jayaratne


Date



29/12/09

Professor S Sivayogan

Date




28/12/09

Professor S Kathriarachchi

Date

I hereby certify that the candidate has made all the corrections/ amendments suggested by the examiners at the viva voce examination.



Prof S Sivayogan

Professor in Community Medicine

TABLE OF CONTENTS

TABLE OF CONTENTS	1
LIST OF TABLES	8
LIST OF FIGURES	10
LIST OF ABBREVIATIONS	12
ACKNOWLEDGEMENTS	15
ABSTRACT.....	17
PUBLICATIONS AND COMMUNICATIONS.....	20
1 INTRODUCTION.....	22
1.1 EPIDEMIC OF DIABETES	23
1.2 ERECTILE DYSFUNCTION IN DIABETES.....	25
1.3 PREMATURE EjACULATION, REDUCED LIBIDO AND OTHER ASSOCIATIONS OF ED	26
1.4 QUALITY OF LIFE AND DIABETIC ED	26
1.5 THE OBJECTIVES OF THE SRI LANKAN STUDY.....	28
1.6 THE COMPARATIVE STUDY IN BROADER GROUP OF SOUTH ASIAN'S WITH EUROPID AND NON DIABETIC CONTROL GROUPS	28
1.7 USE OF GP HELD RECORDS AND POSTAL QUESTIONNAIRE.....	29
1.8 LINGUISTIC VALIDATION	31
1.9 OBJECTIVES OF THE COMPARATIVE STUDY.....	31
1.9.1 <i>Stage 1</i>	31
1.9.2 <i>Stage 2</i>	32

2 LITERATURE REVIEW.....	33
2.1 THE ETIOLOGICAL CLASSIFICATION OF DIABETES.....	34
2.2 PATHOPHYSIOLOGY OF TYPE 2 DIABETES	35
2.3 SEXUAL DYSFUNCTION	37
2.3.1 <i>History and Epidemiology of Male Sexual Dysfunction</i>	37
2.3.2 <i>Anatomy of the Penis.....</i>	39
2.3.3 <i>Penile Innervation.....</i>	41
2.4 PENILE INNERVATION	42
2.4.1 <i>Physiology of Erection</i>	42
2.5 CLASSIFICATION OF ERECTILE DYSFUNCTION.....	44
2.5.1 <i>Psychogenic Erectile Dysfunction</i>	45
2.5.2 <i>Neurogenic Erectile Dysfunction.....</i>	46
2.5.3 <i>Hormonal Causes of Erectile Dysfunction</i>	46
2.5.4 <i>Vascular Causes of Erectile Dysfunction.....</i>	47
2.5.5 <i>Drug-Induced Erectile Dysfunction.....</i>	47
2.5.6 <i>Erectile Dysfunction Due to Other Systemic Diseases and Aging.....</i>	48
2.6 ERECTILE DYSFUNCTION IN DIABETES.....	49
2.7 EPIDEMIOLOGY OF ERECTILE DYSFUNCTION IN DIABETES.....	50
2.8 RISK FACTORS AND ASSOCIATIONS	56
2.9 THE PATHOPHYSIOLOGY OF ED IN DIABETES	57
2.9.1 <i>Psychological and Relationship Issues</i>	58
2.9.2 <i>Organic Factors.....</i>	60
2.9.2.1 Vasculopathy	60
2.9.2.2 Peripheral and Autonomic Neuropathy.....	62
2.9.2.3 Hypogonadism.....	63

2.9.2.4	Peyronie's Disease, Fibrosis, Balanitis and Phimosis	65
2.10	MANAGEMENT OF DIABETIC MEN WITH ED.....	68
2.10.1	<i>Evaluation</i>	68
2.10.2	<i>Psychosexual Management</i>	70
2.10.3	<i>Risk Factor Modification</i>	70
2.10.4	<i>Phosphodiesterase -5 inhibitors: Sildenafil, Tadalafil and Vardenafil.</i> ..	72
2.10.5	<i>Vasoactive Substances</i>	74
2.10.6	<i>Testosterone Supplementation</i>	75
2.10.7	<i>Vacuum Erection Devices and Penile Implants</i>	77
3	PATIENTS AND METHODS	80
3.1	SRI LANKAN STUDY	81
3.1.1	<i>Patients</i>	81
3.1.2	<i>The assessment of sexual dysfunction</i>	81
3.1.3	<i>The assessment of quality of life</i>	83
3.1.4	<i>Other Clinical Variables</i>	87
3.1.5	<i>Examination</i>	87
3.1.6	<i>Investigations</i>	88
3.1.6.1	<i>HbA_{1c} Assessment</i>	88
3.1.6.2	<i>Cholesterol Assessment</i>	89
3.1.6.3	<i>Serum Creatinine Assessment</i>	89
3.1.7	<i>Data Analysis</i>	89
3.1.8	<i>Ethical Considerations</i>	90
3.2	THE COMPARATIVE STUDY (OXFORD SEXUAL DYSFUNCTION STUDY)	91
3.2.1	<i>Stage 1 -Linguistic Validation</i>	91
3.2.2	<i>Stage 2- GP Practice Based Study</i>	94

3.2.2.1	Inclusion Criteria	94
3.2.2.2	Exclusion Criteria	95
3.2.2.3	Participant Selection and Recruitment	95
3.2.2.3.1	GP Practice Recruitment.....	95
3.2.2.3.2	Participants – Diabetic group.....	95
3.2.2.3.3	Control Group	96
3.2.2.4	Recruitment	97
3.2.2.5	Data Collection	99
3.2.2.5.1	Self-administered questionnaires	99
3.2.2.5.2	Clinical, Biochemical, Co morbid Factors, Complications and Medication.....	100
3.2.2.5.2.1	Anthropometric Data.....	100
3.2.2.5.2.2	Clinical Data	100
3.2.2.5.2.3	The Prescription Medication.....	101
3.2.2.5.2.4	Biochemical Data.....	102
3.2.2.5.2.5	Variables Calculated	102
3.2.2.5.2.6	The Index of Multiple Deprivation	103
3.2.2.6	Data Management	104
3.2.2.6.1	Data Protection.....	104
3.2.2.6.2	Data Entry	104
3.2.2.7	Statistical Considerations	104
3.2.2.7.1	Sample Size Calculation	104
3.2.2.7.2	Statistical Methods	105
3.2.2.8	Regulatory and Ethical approvals	107

4	RESULTS	108
4.1	THE SRI LANKAN STUDY	109
4.1.1	<i>The Sample Characteristics.....</i>	109
4.1.2	<i>Prevalence of ED and other sexual dysfunction.....</i>	110
4.1.3	<i>The Univriate Associations of ED.....</i>	113
4.1.4	<i>Premature Ejaculation and Reduced Libido</i>	115
4.1.5	<i>Multivariate Analysis</i>	119
4.1.6	<i>Quality of Life- Generic QOL.....</i>	120
4.1.7	<i>Disease Specific Quality of Life.....</i>	125
4.1.8	<i>Help Seeking Behavior and Treatment History.....</i>	128
4.2	LINGUISTIC VALIDATION	129
4.2.1	<i>The Cultural Issues Encountered.....</i>	129
4.2.2	<i>Conceptual/Semantic Issues Encountered.....</i>	130
4.3	THE COMPARATIVE STUDY	133
4.3.1	<i>The Recruitment.....</i>	136
4.3.1.1	<i>The Approached Sample</i>	136
4.3.2	<i>Response rates and factors affecting response to initial invitation</i>	140
4.3.3	<i>Factors Affecting the Completion of the Questionnaire.....</i>	145
4.3.4	<i>Socio Demographic and Life Style Characteristics of the Study Completed Group.</i>	148
4.3.5	<i>The Clinical Characteristics of the Study Population.....</i>	151
4.3.6	<i>The Biochemical Parameters of the Study Population.....</i>	151
4.3.7	<i>Macrovascular and Microvascular complications</i>	158
4.3.8	<i>The Medication Usage of the Study Population</i>	158
4.3.9	<i>The Assessment of Erectile Dysfunction.....</i>	162

4.3.9.1	Erectile Dysfunction Assessed using IIEF-5(SHIM).....	162
4.3.9.2	Erectile function assessed using Erection Hardness Score	162
4.3.9.3	Erectile Dysfunction Assessed by Direct Question	163
4.3.10	<i>Premature Ejaculation</i>	163
4.3.11	<i>Reduced Libido</i>	164
4.3.12	<i>Severity grades of ED and their association with other sexual dysfunctions</i>	167
4.3.13	<i>Associations of ED</i>	168
4.3.13.1	Socio demographic and life style associations of ED	168
4.3.13.2	Clinical associations of ED	170
4.3.13.3	Biochemical associations of ED	171
4.3.13.4	Micovascular and micro vascular associations of ED	172
4.3.13.5	Medication usage and their associations with ED	173
4.3.14	<i>Associations of Premature Ejaculation</i>	174
4.3.14.1	Clinical and biochemical associations of PE.....	175
5	DISCUSSION	177
5.1	SRI LANKAN STUDY	178
5.1.1	<i>Diabetic Erectile Dysfunction</i>	178
5.1.2	<i>Other Sexual Dysfunction Associated</i>	179
5.1.3	<i>Clinical, socioeconomic and lifestyle associations of ED</i>	182
5.2	THE ASSESSMENT OF QUALITY OF LIFE	184
5.3	HEALTH SEEKING BEHAVIOUR	188
5.4	THE COMPARATIVE STUDY (OXFORD SEXUAL DYSFUNCTION STUDY)	189
5.4.1	<i>Linguistic validation of the questionnaire</i>	189

5.4.2	<i>Feasibility of GP practice based study and the factors affecting recruitment and completion.....</i>	192
5.4.3	<i>The differences in population characteristics.....</i>	200
5.4.4	<i>Differences in Erectile Dysfunction</i>	201
5.4.5	<i>Differences in Premature Ejaculation.....</i>	202
5.4.6	<i>Sexual Associations of ED.....</i>	203
6	CONCLUSIONS & RECOMMENDATIONS	204
6.1	SRI LANKAN STUDY.....	205
6.1.1	<i>Erectile Dysfunction and its Associations</i>	205
6.1.2	<i>Quality of Life</i>	206
6.2	THE COMPARATIVE STUDY	207
6.2.1	<i>Linguistic Validation Process.....</i>	207
6.2.2	<i>Feasibility of GP Practice Based Study</i>	207
6.2.3	<i>The Factors Affecting Response Rate</i>	208
6.2.4	<i>The Differences in Population Characteristics</i>	208
6.2.5	<i>Differences in Erectile Dysfunction</i>	209
6.2.6	<i>Differences in Premature Ejaculation.....</i>	209
6.2.7	<i>Overall Recommendations.....</i>	210
REFERENCES.....		211
APPENDICES		237

LIST OF TABLES

TABLE 2-1 CLASSIFICATION OF COMMON CAUSES OF ERECTILE DYSFUNCTION.....	45
TABLE 2-2 COMPARISON OF ED PREVALENCE STUDIES IN DIABETES	54
TABLE 3-1 EIGHT DIMENSIONS OF SF36	84
FIGURE 3-1 SF-36 SCALES MEASURE PHYSICAL AND MENTAL COMPONENTS OF HEALTH	
.....	86
TABLE 4-1 THE SOCIODEMOGRAPHIC CHARACTERISTICS OF THE STUDY POPULATION	110
TABLE 4-2 ASSESSMENT OF ERECTILE FUNCTION USING IIEF 5	111
TABLE 4-4 CLINICAL ASSOCIATIONS OF ED (UNIVARIATE ANALYSIS)	114
TABLE 4-5 SOCIO ECONOMIC ASSOCIATIONS OF ED (UNIVARIATE).....	115
TABLE 4-6 ASSOCIATION OF OTHER ASPECTS OF SEXUAL FUNCTION WITH SEVERITY	
GRADES OF ED.....	117
TABLE 4-7 VARIABLES SIGNIFICANTLY ASSOCIATED WITH PRESENCE OF ED (ANY	
DEGREE OF ED) IN MULTIVARIATE ANALYSIS.	119
TABLE 4-8 VARIABLES ASSOCIATED WITH MODERATE TO COMPLETE ED (COMPARED	
WITH NORMAL ERECTILE FUNCTION) IN THE MULTIVARIATE ANALYSIS.....	120
TABLE 4-9 PREDICTORS OF EIGHT SUBSCALES OF SF36 IN LINER LOGISTIC REGRESSION	
MODEL FOR EACH SUBSCALE.....	124
TABLE 4-10 PREDICTORS OF TWO SUMMERY SCALES OF SF36 IN LINEAR LOGISTIC	
REGRESSION MODEL FOR EACH SUMMERY SCALE.....	125
TABLE 4-11 PREDICTORS OF TWO SCALES OF PIED IN MULTIVARIATE LINEAR LOGISTIC	
REGRESSION MODEL	128
TABLE 4-14 MEAN AGE AND THE IMD SCORES FOR THE RECRUITED MEN	139
TABLE 4-15 COMPARISON OF RECRUITED MEN WITH REGARDS TO DIABETES STATUS	
AND ETHNICITY	142

TABLE 4-16 FACTORS AFFECTING RECRUITMENT AND COMPLETION	144
TABLE 4-17 THE MEAN AGES AND IMD SCORES FOR THE STUDY COMPLETED GROUP	146
TABLE 4-19 LIFESTYLE CHARACTERISTIC COMPARISON FOR DIABETES STATUS AND ETHNICITY	150
TABLE 4-20 COMPARISON OF CLINICAL PARAMETERS WITH REGARD TO DIABETES STATUS & ETHNICITY	153
TABLE 4-21 COMPARISON OF BIOCHEMICAL PARAMETERS WITH REGARD TO DIABETES STATUS AND ETHNICITY.....	155
TABLE 4-22 COMPARISON OF FURTHER BIOCHEMICAL PARAMETERS WITH REGARDS TO DIABETES STATUS AND ETHNICITY.....	156
TABLE 4-23 COMPARISON OF MACROVASCULAR AND MICROVASCULAR COMPLICATIONS WITH REGARD TO DIABETES STATUS & ETHNICITY	159
TABLE 4-24 COMPARISON OF MEDICATION USE WITH REGARD TO DIABETES STATUS & ETHNICITY	160
TABLE 4-25 ERECTILE DYSFUNCTION PREVALENCE RATE COMPARISON FOR DIABETES STATUS AND ETHNICITY.....	165
TABLE 4-26 THE RESPONSE RATES FOR PE AND LIBIDO QUESTIONNAIRE AND THE PREVALENCE FOR PE AND REDUCED	166
TABLE 4-27 ASSOCIATION OF ERECTILE FUNCTION IIEE-5 (ORDINAL) WITH PREMATURE EJACULATION AND REDUCED LIBIDO	168
TABLE 4-28 UNIVARIATE SOCIO-DEMOGRAPHIC/LIFESTYLE ASSOCIATIONS OF ED....	169
TABLE 4-29 UNIVARIATE CLINICAL ASSOCIATIONS OF ED.....	170
TABLE 4-30 UNIVARIATE BIOCHEMICAL ASSOCIATIONS OF ED	171
TABLE 4-31 UNIVARIATE MACRO/MICRO VASCULAR COMPLICATIONS	172
TABLE 4-32 UNIVARIATE ASSOCIATIONS OF MEDICATION USAGE WITH ED	173

TABLE 4-33 UNIVARIATE ASSOCIATIONS OF PE WITH SOCIO-DEMOGRAPHIC/ LIFESTYLE CHARACTERISTICS	174
TABLE 4-34 UNIVARITE CLINICAL ASSOCIATIONS OF PE	175
TABLE 4-35 UNIVARIATE BIOCHEMICAL ASSOCIATIONS OF PE	176

LIST OF FIGURES

FIGURE 2-1 ANATOMY OF THE PENIS-CROSS SECTION.....	40
FIGURE 2-2 SCHEMATIC DIAGRAM SHOWING THE SINUSOIDAL ANATOMY IN FLACCID AND ERECT STATES.....	40
FIGURE 2-3 THE ARTERIAL SUPPLY AND THE VENOUS DRAINAGE OR THE PENIS	41
FIGURE 2-4 PENILE INNERVATION.....	42
FIGURE 2-5 THE MOLECULAR BIOLOGY OF ERECTIONS	44
FIGURE 2-6 PATHOPHYSIOLOGY OF DIABETIC ED	67
FIGURE 2-7 MANAGEMENT OF DIABETIC ED	79
FIGURE 3-1 SF-36 SCALES MEASURE PHYSICAL AND MENTAL COMPONENTS OF HEALTH	86
FIGURE 3-2 PATIENT RECRUITMENT AND DATA COLLECTION.....	98
FIGURE 4-1 PREVALENCE OF ED, PE AND REDUCED LIBIDO IN DIFFERENT AGE CATEGORIES	112
FIGURE 4-2 ASSOCIATION OF PREMATURE EJACULATION WITH SEVERITY GRADES OF ED	118
FIGURE 4-3 ASSOCIATION OF REDUCED LIBIDO WITH SEVERITY GRADES OF ED	118
FIGURE 4-4 – CHANGES IN SF36 PHYSICAL HEALTH SUMMARY SCALE WITH CHANGES IN ERECTILE FUNCTION	121

FIGURE 4-5 CHANGES IN SF36 MENTAL HEALTH SUMMARY SCALES WITH CHANGES IN ERECTILE FUNCTION.....	122
FIGURE 4-6 CHANGES IN SEXUAL EXPERIENCE SCALE WITH FIVE CATEGORIES OF ERECTILE FUNCTION.....	126
FIGURE 4-7 CHANGES IN EMOTIONAL EXPERIENCE SCALE WITH FIVE CATEGORIES OF ERECTILE FUNCTION.....	127
FIGURE 4-8 RECRUITMENT -FLOW CHART.....	137

LIST OF ABBREVIATIONS

5-HT	5-Hydroxytryptamine
ACEIs	Angeotensin converting enzyme inhibitors
ACH	Acetylecholine
AGEs	Advanced Glycation end products
ALP	Alkaline Phosphatase
ALT	Alanine Amino Transferese
ANOVA	Analysis of Variance
ARBs	Angiotensin Converting Enzyme Inhibitors
BMI	Body Mass Index
BP	Blood Pressure
cAMP	Cyclic Adenosine Mono Phosphate
cGMP	Cyclic Guanosine monophosphate
CSTH	Colombo South Teaching Hospital
DPS	Diabetes Prevention Study
ED	Erectile Dysfunction
EHS	Erection Hardness Score
FBS	Fasting Blood Sugar
GFR	Glomerular Filtration Rate
GP	General Practitioner
HbA1c	Glycosylated Haemoglobin A1c
HDL	High Density Lipoproteins
IDPP	Indian Diabetes Prevention Program

IFG	Impaired Fasting Glucose
IGT	Impaired Glucose Tolerance
IIEF5	5 Item International Index of Erectile Function
IMD	Index of Multiple Deprivation
LDL	Low Density Lipoproteins
MUSE	Medicated Urethral System for Erection
NHS	National Health Service of the UK
NK	Not Known
NO	Nitric Oxide
NOS	Nitric Oxide Synthase
OGTT	Oral Glucose Tolerance Test
PCT	Primary Care Trust
PDE5 inhibitors	Phosphodiesterase 5 inhibitors
PE	Premature Ejaculation
PEDT	Premature Ejaculation Diagnosis Tool
PGE-1	Prostaglandin E-1
PKG-1	cGMP dependent kinase-1
QoL	Quality of Life
RL	Reduced Libido
ROS	Reactive Oxygen Species
SD	Standard Deviation
SES	Sexual Excitation Score
SF-36	Short Form-36
SHBG	Sex Hormone Binding Globulin
SHIM	Sexual Health Inventory for Men

SIS	Sexual Inhibition Score
TG	Triglycerides
TIA	Transient Ischaemic Attack
TSH	Thyroid Stimulating Hormone
UK	United Kingdom
USA	United States of America
VIP	Vasoactive Intestinal Polypeptide
WHO	World Health Organisation

ACKNOWLEDGEMENTS

The work presented in this thesis would not have been possible without the support of many individuals to whom I am extremely grateful. First of all, I thank with greatest respect my supervisors Prof S D Jayaratne, Department of Medicine, Prof S Kathriarachchi, Department of Psychiatry and Prof S Sivayogan, Department of Community Medicine, Faculty of Medical Sciences, University of Sri Jayawardenapura and Dr J C Levy, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford for their inspiration, wisdom, extremely valuable support and guidance throughout.

I thank Dr J C Levy sincerely for the great opportunity given to me to work in Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford. I am also grateful to him for his invaluable academic supervision in this work and his kindness and generosity during my four years of stay in Oxford.

Prof David Matthews, the professor of Diabetic Medicine, University of Oxford and the chairman of Oxford Centre for Diabetes, Endocrinology and Metabolism is acknowledged and thanked for all his help, guidance and encouragement.

The valuable contribution of Prof John Bancroft, the former director of Kinsey Institute who is widely regarded as the world leader in Sexual Medicine is acknowledged for all his advice and guidance.

Prof Irene Stratton is acknowledged for her valuable advice on statistical methods.

Dr Anne Clarke is acknowledged for her encouragement and guidance. I also thank my friends, colleagues, clinicians and administrators at the Oxford University specially Dr Nathan Hill, Dr Prasad Katulanda, Dr Nikki Meston, Dr Nikki Karawitake, Ms Carol Hill, Mr Edward Gibbs and Miss Louise Williams for their friendship and support.

I thank my collaborators from eight primary care trusts and the doctors of 25 GP practices who helped with the study. All those who took part in Sri Lankan and the UK studies are thanked sincerely for their generosity.

Pfizer Global and the Oxford University are acknowledged for funding the research work carried out in the UK. Bayer Schering Phamra is thanked for financing the printing costs of the patient information booklet which was distributed among the participants of the study.

I also would like to thank Dr Upeksha Ratnayake, Dr Pabasi Wijesekara and Dr Dhanesha Seneviratene- Epa for their extremely useful contribution in different stages of data collection and patient recruitment.

I thank my parents with the greatest respect for all what they have done for me and their unconditional love, encouragement and for being the most amazing parents. I thank sincerely my sister who always stood behind me for looking after my other concerns during this work.

At last but not the least, I would like to thank my wife Neelika, daughter Sauni and little son Thenuka for their love, comfort, understanding and patience specially during long stays away from the family. I thank my in-laws for their support and looking after Sauni and Thenuka during my absence from the country, giving me some freedom in mind to concentrate on this work.

ABSTRACT

Introduction Diabetes is reaching pandemic levels and South Asians are at increased risk of developing diabetes and diabetic complications. Erectile Dysfunction (ED) defined as inability to achieve or maintain an erection for satisfactory sexual intercourse is a common complication of diabetes. Despite higher predisposition to diabetes, this complication has never been studied (no published data available) among South Asian men with diabetes. The work presented in this thesis were carried out in two components and presented as the Sri Lankan study and the Oxford Sexual Dysfunction Study.

Objectives of the Sri Lankan Study

General Objective

To determine the proportion of ED among a sample of Sri Lankan diabetic men and to describe its associations.

Specific Objectives

1. To determine the proportion of Erectile Dysfunction in diabetic patients attending clinic in Colombo South Teaching Hospital.
2. To describe the association of Erectile Dysfunction with Premature Ejaculation and Reduced Libido.
3. To describe clinical, socio economic and life style associations of Erectile Dysfunction.
4. To describe psychological impact and quality of life using validated scales.

Objectives of the Oxford Sexual Dysfunction Study

Stage1

To linguistically validate set of questionnaire in to Hindi, Urdu, Panjabi, Tamil and Sinhalese.

Stage 2

1. To assess the feasibility of using validated postal questionnaires and GP records to assess sexual dysfunction in a primary care setting in diabetic and non diabetic men of South Asian and Europid ethnic extraction and determine factors affecting recruitment and study completion.
2. To estimate the prevalence of Erectile Dysfunction, premature ejaculation and reduced libido in South Asian individuals with diabetes compared Europid men with diabetes and their age matched non diabetic controls.
3. To determine the associations between Erectile Dysfunction, Premature Ejaculation and Reduced Libido.
4. To determine clinical, biochemical, socio economic and life style associations of Erectile Dysfunction in both diabetic and non diabetic men.

Methods Sri Lankan Study- A cross sectional descriptive study carried out in Colombo South Teaching hospital diabetic clinic using validated scales, structured interviewer administered questionnaire, physical examination, clinical records and laboratory investigations.

Oxford Study- The linguistic validation was carried out by adopting internationally accepted methodology which included pilot testing with five volunteers for each language version.. The stage 2 was a GP practice based cross sectional descriptive study using clinical data available in the GP records and the set of postal questionnaire. This study was carried out in 25 GP practices from 8 primary care trusts using clinical data held by the GP records and a set of postal questionnaire.

Results- I found very high proportion (73%) diabetic men to have some degree of erectile dysfunction. I also found erectile dysfunction to be strongly associated with

premature ejaculation ($p=0.0001$) and reduced libido ($p=0.0001$) together with several important clinical and socio economic and life style associations. Erectile dysfunction was found to be associated with poor quality of life assessed by both generic and disease specific quality of life measures.

A set of useful scales in sexual medicine were linguistically validated into Hindi, Urdu, Panjabi, Tamil and Sinhalese. The overall recruitment rate was low and was influenced by ethnicity, diabetes status, age and area based deprivation index. I found high prevalence of erectile dysfunction in diabetic men compared to non diabetic men ($p<0.001$). No ethnic difference in erectile dysfunction prevalence was found in diabetic men. However, South Asian non diabetic men had significantly higher prevalence of erectile dysfunction compared to their non diabetic Europid counterparts ($p=0.04$). The strong association we found in the Sri Lanka study between erectile dysfunction and premature ejaculation was found in larger group of participants irrespective of their diabetes status and ethnicity. Other interesting and novel finding was the significantly higher proportion of men of South Asian origin having premature ejaculation in both diabetic ($p=0.001$) and non diabetic groups ($p=0.001$). The high prevalence of premature ejaculation in South Asians needs to be investigated further in order to identify aetiology for this.

Conclusions- Erectile dysfunction in diabetes a common and serious quality of life issue. Clinician managing diabetic patients should take a holistic approach in managing diabetes related erectile dysfunction as it is associated with premature ejaculation, reduced libido, poor glycaemic control, hypertension and many other clinical socio economic and life style factors.